Introduction
Primary infection by human immunodeficiency virus type 1 (HIV-1) is typically associated with an initial peak of plasma viraemia and its subsequent decline to various levels (Henrard et al., 1995 ; Mellors et al., 1996 ; Clark et al., 1991) . The plasma virus level is a predictor of progression to the disease state (Ho et al., 1989 ; Mellors et al., 1995) . The development of an animal model capable of mimicking high plasma viraemia followed by virus-induced CD4 + cell loss and AIDS has been attempted. In early animal models, such as simian\human immunodeficiency viruses (SHIV) in macaque monkeys and HIV-1 in chimpanzees, a limited infection was established that did not progress to the overt disease state (Shibata et al., 1991 ; Li et al., 1992 ; Author for correspondence : Mitsuo Honda.
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The env V3, TM and nef sequences of SHIV-C2/1 have been submitted to GenBank under accession numbers AF082831 and AF082832.
1996 a). The current animal model of SHIV has been used to develop pathogenic models of HIV infection in macaque monkeys Stephens et al., 1996 ; Karlsson et al., 1997 ; Lu et al., 1998 ; . In some of these models, pathogenic SHIV-89.6P and SHIV-89.6PD were isolated as a result of the serial passage of SHIV-89.6 to produce monkey models of HIV-1 disease in humans. By using bone marrow-tobone marrow transfer of SHIV-HXBc2 in pig-tailed macaques, a virulent SHIV, KU-1, was also obtained . High doses of these stock viruses were transmitted to macaque monkeys by intravenous, intrarectal and intravaginal inoculation. The CD4 + cell count decreased in the peripheral blood substantially or rapidly in most of the animals tested (Steger et al., 1998) .
The sequence changes in the pathogenic virus genomes were characterized by limited numbers of amino acid substitutions in the gp120, vpr, tat and nef regions that might have converted the virus to cause AIDS in pig-tailed macaques (Stephens et al., 1997) . Recently, Karlsson et al. (1997) characterized the molecular changes of the proviral clones of SHIV-89.6P and revealed that the exterior domain of the carboxy terminus of SIVmac gp41 was replaced by HIV-1 gp41 glycoprotein and that amino acid mutations were detected in the gp120 protein. These nucleotide changes are potentially responsible for the increase in virulence of these viruses.
Although we inoculated p-SHIV (SHIV that contains the env gene of the pathogenic strain HIV-89.6 and is pathogenic in rhesus monkey) into cynomolgus monkeys, CD4 + cell depletion was not detected more than 6 months after virus inoculation in this study. However, by serial in vivo serum passages, we produced a strain of SHIV, designated C2\1, that was highly pathogenic in cynomolgus monkeys and which reproducibly induced a rapid decrease in CD4 + T cells in the peripheral blood as well as in other lymphoid tissues. Pathogenicity was associated with specific amino acids changes in the envelope glycoproteins and Nef protein.
Methods
Animals. All cynomolgus monkeys (Macaca fascicularis) used in the study were maintained according to the guidelines of the Institutional Animal Care and Use Committee of the National Institute of Infectious Diseases (NIID), Japan, and standard operating procedures for monkeys for evaluation of human vaccines in the Tsukuba Primate Center, NIID, Tsukuba, Ibaraki, Japan. The study was conducted in accordance with the requirements specifically stated in the Laboratory Biosafety Manual, World Health Organization, in the P3 facility for monkeys in Murayama Branch, NIID, Musashimurayama, Tokyo, Japan.
Viruses.
Challenge virus stocks of non-pathogenic strain SHIV-MN and p-SHIV were used directly for the challenge experiment Lu et al., 1996 b) . Chimeric viruses for in vitro assays were propagated in ConA-activated, monkey peripheral blood mononuclear cells (PBMC) from normal animals or in cell line M8166. The amount of virus was measured by SIV p27 antigen ELISA (Coulter Electronics). Cellfree virus stocks were stored at k120 mC.
Antibodies. The mouse monoclonal antibodies (MAbs) used in this study were fluorescein isothiocyanate (FITC)-or phycoerythrin (PE)-conjugated MAbs to monkey CD3 (NF-18 ; BioSource) and to human CD4 (Nu-T H/I ; Nichirei), CD8 (Nu-T S/C ; Nichirei), CD16 (3G8 ; Pharmingen) and CD20 (Leu-16 ; Becton Dickinson).
Serological analysis. SHIV-seropositive monkeys were identified by routine Western blot analysis for HIV-1 (Diagnostics Pasteur).
ELISA for antibodies to p27 protein in plasma. An ELISA was established to detect the antibody titre against recombinant SIVmac239 Gag protein in a similar way to that described previously (Yamanaka et al., 1997 ; Binley et al., 1997) . Briefly, recombinant p27 was expressed, purified and coated on a microtitre plate at 2 µg\ml. Plasma samples were titrated by six serial threefold dilutions ; initial dilution of samples was 1 : 300. Bound anti-p27 antibody was detected by peroxidase-conjugated, anti-cynomolgus monkey IgG (Immunology Biology Laboratory, Gunma, Japan) and the TMBj system (DAKO). The mean antibody titre was expressed as the reciprocal of the serum dilution that reached the cutoff value plus 2 SD.
Preparation of tissues and blood samples for cell surface antigen analysis by flow cytometry. For cell surface antigen analysis, peripheral blood was mixed with lysis buffer (Becton Dickinson) and after centrifugation at 300 g for 5 min, the cells were counted by the trypan blue dye-exclusion method. The antigens CD3, CD4, CD8, CD16 and CD20 were stained with their respective MAbs. After being washed with staining buffer, 5i10% cells of each labelled sample were analysed by a FACSCalibur flow cytometer (Becton Dickinson) using the Cell Quest software (Becton Dickinson). The absolute PBMC count was determined as follows. Fifty µl of each whole blood sample, containing FITCconjugated anti-CD3 MAb (BioSource), PE-conjugated anti-CD4 MAb (Becton Dickinson) and peridinin-chlorophyll protein-conjugated anti-CD8 MAb (Becton Dickinson), was added to a TRUCOUNT tube and incubated at room temperature and then red blood cells were lysed. Each sample was analysed by flow cytometry as described above and all measurements were made at the same instrument setting. The mean leukocyte and CD4 + T lymphocyte counts were 5951 and 1941, respectively. CD4 + T lymphocyte percentage was 52p12 in cynomolgus monkeys.
Quantification of cell-associated and plasma virus load by virus isolation. Cell-associated virus loads were quantified by limiting dilution of PBMC from 10' cells to 1 cell, as described by Honda et al. (1992) and Lehner et al. (1996) . M8166 cells were used for coculture and generation of the virus in the culture supernatant was quantified by p27 antigen ELISA (Coulter). The smallest number of PBMCs required to produce a positive culture was taken as the end-point of virus infection and the titres of the infectious virus were expressed as TCID &! per 10' PBMC.
PCR amplification and sequencing of virus RNA. Poly(A) + RNA was isolated from plasma of infected cynomolgus monkeys by using the Micro-FastTrack kit as suggested by the manufacturer (Invitrogen). RT-PCR was performed by using the ACCESS RT-PCR System (Promega). Reverse transcription was carried out at 48 mC for 60 min with AMV reverse transcriptase and was followed by first-round PCR with Tfl DNA polymerase under the following conditions : one cycle of 94 mC for 2 min ; 40 cycles of 94 mC for 30 s, 45 mC for 1 min, 68 mC for 5 min ; and one cycle of 68 mC for 7 min. The second-round PCR was performed with Taq DNA polymerase under the following conditions : one cycle of 94 mC for 3 min ; 30 cycles of 94 mC for 30 s, 55 mC for 1 min, 72 mC for 2 min ; and one cycle of 72 mC for 7 min. For the env V3 region, nested primer pairs OA3 and SD (RT and first-round PCR) and SB and SC (second-round PCR) were used. For the env gp41-nef junction region, nested primer pairs GBK-1005 (j) and P16777 (RT and first-round PCR) and GBK-1012 (j) and P16775 (second-round PCR) were used. For the nef gene, nested primer pairs 8632F and 9980R (RT and first-round PCR) and 8690F and 9927R (second-round PCR) were used. The sequences of the primers were as follows (name, position, sequence) : OA3, 7086-7110, 5h TGTACACATGGAATTAGGCCA-GTAG 3h ; SD, 7467-7487, 5h AAATTCCCCTCCACAATTAAA 3h ; SB, 7113-7133, 5h TCAACTCAACTGCTGTTAAAT 3h ; SC, 7432-7454, 5h AATTTCTGGGTCCCCTCCTGAGG 3h ; GBK-1005 (j), 8517-8541, 5h AGGCCCGAAGGAACAGAAGAAGAAG 3h ; P16777, 9006-9033, 5h CATCTTCCACCTCTCCTAAGAGTCTCCC 3h ; GBK-1012 (j), 8543-8563, 5h TGGAGAGAGAGACAGAGACAG 3h ; P16775, 8964-8989, 5h GCCCGCAAGAGTCTCTGTCGCAGATC 3h ; 8632F, 8632-8648, 5h GCTACCACCGCTTGAGA 3h ; 9980R, 9807-9825, 5h TGAATACAGAGCGAAATGC 3h ; 8690F, 8690-8707 SHIV highly pathogenic in cynomolgus monkey SHIV highly pathogenic in cynomolgus monkey ACGCAGGGGGTGGGAAGC 3h ; 9927R, 9753-9771, 5h GACCGG-CTCCTCCCCAGTA 3h. The positions of the oligonucleotides are numbered relative to the SHIV-89.6 isolate (GenBank accession no. AF038398).
Sequences of env V3 and nef regions were determined directly from the PCR products by using the Dye Terminator Cycle Sequencing FS kit and an ABI PRISM 310 Genetic Analyser (PE Applied Biosystems) as described previously (Honda et al., 1995 ; Karlsson et al., 1997 ; Li et al., 1995) . Additional primers used for sequencing were : 9307F, 9152-9175, 5h AGAAAAATTAGCATACAGAAAACA 3h ; 9620F, 9465-9485, 5h GTATCAGATGAGGCACAGGAG 3h ; 9305R, 9158-9178, 5h TTTT-GTTTTCTGTATGCTAAT 3h ; 9635R, 9458-9480, 5h GTGCCTC-ATCTGATACATTTACA 3h.
Results
Production of a highly pathogenic SHIV, C2/1, in cynomolgus monkeys by in vivo passage of SHIV Since cynomolgus monkeys are conveniently used for evaluation of various vaccines, we tried to obtain a pathogenic SHIV as an HIV\AIDS model in cynomolgus monkeys (Table  1) . We injected a monkey (CY-1) with 1n2i10% TCID &! p-SHIV. Initial viraemia was observed within 3 weeks after virus inoculation but depletion of CD4 + lymphocytes was detected as late as 6 months after inoculation. We performed serial in vivo passages in cynomolgus monkeys of sera of infected animals in the initial viraemic stage (Table 1 ). The plasma isolated from monkey CY-1 was designated SHIV-C1\1 ; its infectious titre was 560 TCID &! and it was used as the source for virus passage. Twenty-three weeks post-inoculation (p.i.), a second plasma viraemia was detected and the CD4 + lymphocyte count had decreased to fewer than 10 cells per µl (less than 10 % of total lymphocytes) (Fig. 1 a) . At the time of One ml of SHIV-C1\1 virus-containing plasma was injected into each of two monkeys, CY-2 and CY-3. CD4 + cell counts in both monkeys decreased abruptly to fewer than 10 cells per µl at 2 weeks p.i. and the decreased CD4 + cell counts were maintained (data not shown). The plasma that was obtained from CY-2 at 14 days p.i. contained 650 TCID &! \ml. This sample was designated SHIV-C2\1 and was used as the virus source for the second plasma passage (Table 1) . Twenty TCID &! SHIV-C2\1 was further passaged to seven monkeys, animals CY-4 to CY-10 (Table 1 and Fig. 2 ). All seven monkeys in which the stock virus was passaged showed rapid depletion of plasma CD4 + cells at 12 days p.i. (Fig. 2 a) . This CD4 + cell depletion was maintained in all C2\1-infected animals studied and until 12 weeks p.i. in monkeys CY-6 and CY-7 (Fig. 2 a) . Levels of other CD8 + and B lymphocytes also decreased moderately in these monkeys. In contrast, monocyte and granulocyte counts did not change throughout the experiments (data not shown). Plasma antigenaemia in each monkey infected with 20 TCID &! SHIV-C2\1 was very high, between 1n1 and 2n1 ng\ml (Table 1) .
After two serial passages of sera derived from the initial viraemia in monkeys, the time of appearance of the peak of initial viraemia was shortened from 3 weeks to 12 days and the virus dose for the inoculation was reduced from 1n2i10% to 20 TCID &! (Table 1) . As a result of inoculation of only 20 TCID &! SHIV-C2\1, all the monkeys showed no further increase in body weight and four of the seven monkeys had diarrhoea approximately 3 weeks p.i. The bone marrow, thymus, spleen, mesenteric lymph nodes, submandibular lymph nodes, axillary lymph nodes, inguinal lymph nodes and peripheral blood were examined for CD4 + and CD8 + cells. CD4 + cells were specifically depleted in all the lymphoid organs from SHIV-C2\1-inoculated monkeys (Table 2) . CD4 + cells were selectively depleted in the thymi of these animals, although CD8 + cells, CD4 + CD8 + cells and CD4 − CD8 − cells remained in these tissues (data not shown). In monkeys inoculated with 20 TCID &! non-pathogenic SHIV-MN, no depletion of lymphocytes was observed in the lymphoid organs or peripheral blood (data not shown) when compared with naive monkeys (Table 1) .
Detection of specific amino acid changes in SHIV Env, gp41 and Nef proteins
In order to determine the molecular changes in the viruses that had occurred during in vivo passage, env gene sequences from p-SHIV, SHIV-C1\1, SHIV-C2\1 and SHIV-C2\2 were examined and the aligned deduced amino acid sequences were compared. As shown in Fig. 3 (a) , the consensus deduced amino acid sequences of the V3 region of 10 clones of the pathogenic SHIV-C strains (SHIV-C1\1, SHIV-C2\1 and SHIV-C2\2) differed by only one amino acid, from arginine to glutamate at position 308, from the sequence of p-SHIV. Changes from asparagine to aspartate at position 279 and from alanine to valine at position 284 in the HIV-1 env C2 region were detected in all the pathogenic SHIV-C strains but not in the original p-SHIV strain.
We also sequenced the junction of the HIV-1 gp41 cytoplasmic tail and the SIVmac239 Nef to study specific mutations or deletions resulting from in vivo serum passage of virus in cynomolgus monkeys (Fig. 3 b) . The deletion of 42 amino acids in the HIV-1 gp41 cytoplasmic tail and the fusion in-frame of 57 amino acids of the SIVmac239 cytoplasmic tail to the rest of the envelope protein, as reported for SHIV-89.6P (Karlsson et al., 1997) , were detected in all pathogenic SHIV-C strains from cynomolgus monkeys. These changes were not detected in the original virus stock of p-SHIV. A stop codon was detected at amino acid position 855 of p-SHIV. Moreover, we detected three conserved amino acid mutations, from leucine-746 to serine, aspartate-756 to alanine and from isoleucine-779 to threonine, in the SHIV Env-Nef junction (Table 1) for in vivo passage of SHIV. The percentage of CD4 + lymphocytes remaining in the seven animals was calculated for each animal by using the day 0 value as 100 %. Data represent the means p SD for the seven monkeys to which SHIV-C2/1 was passaged (n l 2-7). (b) Western blot analysis of plasma from animals CY-6 and CY-7, as shown. Lanes : N, negative control ; Pre, serum sample taken before injection ; 1W-8W, serum samples taken the indicated number of weeks p.i. ; P1, strongly positive control for HIV-1 ; P2, weakly positive control for HIV-1.
region of SHIV-C strains. Fig. 4 shows a stable amino acid change from arginine to lysine at position 109 in the Nef protein of the SHIV-C strains.
The changes at position 279 in the C2 region and at position 308 in the V3 loop in SHIV-C strains, associated with an increase in the negative charge of the protein, and the deletion of 42 amino acids detected in SHIV-C strains may be responsible, together or alone, for the enhanced pathogenicity of SHIV-C strains in cynomolgus monkeys.
Study of SHIV-specific immunity in cynomolgus monkeys inoculated with pathogenic SHIVs
The antibody response after infection with pathogenic SHIVs was studied. Western blotting against HIV-1 was performed with each immune serum, because anti-SIV Gag antibody is known to cross-react with HIV-1 Gag protein antigen. A cynomolgus monkey that had received 1n2i10% TCID &! p-SHIV had antibodies against HIV-1 gp160 and HIV- 1 gp120 from 4 weeks p.i. and maintained the antibody levels until the time of autopsy. Moreover, the animal had crossreactive antibodies against HIV-1 p24 Gag from 5 to 23 weeks p.i. that had disappeared at 26 weeks p.i. (Fig. 1 b) , when depletion of CD4 + cells was detected in the animals (Fig. 1 a) . Interestingly, cynomolgus monkeys infected with SHIV-C1\1 or SHIV-C2\1 developed HIV-1 Env-reactive antibodies but no detectable anti-HIV-1 Gag cross-reactive antibodies (Fig.  2 b) .
We also studied anti-p27 Gag titres in the monkey sera by an ELISA (Fig. 5) . The arithmetic mean of the anti-p27 titres detected at 7 weeks p.i. in monkeys infected with 1n2i10% TCID &! SHIV-MN was 1 : 24 300p19 800 and the titre in p-SHIV-infected monkey serum at the same period was 1 : 8100. In contrast, the antibody titres of the p-SHIV-inoculated monkey at autopsy and SHIV-C2\1-inoculated monkeys at 7 weeks p.i. were less than 1 : 300, which is the detection limit in the standard assay.
Discussion
It has recently been shown that some SHIV strains induce a profound immunodeficient state in rhesus macaques, including CD4 + cell loss Karlsson et al., 1997) . In this study, we obtained a highly pathogenic strain SHIV-C2\1 by serum passage of pathogenic SHIV in cynomolgus monkeys. The original isolate p-SHIV did not cause depletion of CD4 + cells for more than 6 months in cynomolgus monkeys after intravenous inoculation of a large amount of the virus. SHIV-C2\1 infection in cynomolgus monkeys reproducibly led to CD4 + lymphocyte depletion, not only in the peripheral blood but also in various lymphoid organs in all animals tested. The body weight of the animals failed to increase and diarrhoea occurred.
It was important to study the molecular changes that occurred in the virus SHIV-C2\1 during the in vivo passage of p-SHIV resulting in pathogenicity in cynomolgus monkeys. Initially, pathogenic SHIV was produced from a chimeric virus containing the env gene of HIV-1 HXBc2 by serial passage of infectious bone marrow in rhesus and pig-tailed macaques . In regard to the association of genetic changes with enhanced pathogenicity, a limited number of amino acid substitutions in both HIV-1 and SIVmac regions of the genome were found in a pathogenic SHIV, KU-1, after inoculation into animals (Stephens et al., 1997) . To develop an AIDS animal model, Reimann et al. (1996 b) also produced a pathogenic SHIV-89.6P expressing env genes of the primary pathogenic HIV-1 isolate HIV-89.6 after serum passage in rhesus macaques. Moreover, they produced molecular clones of SHIV-89.6P that generated infections in rhesus macaques and induced rapid depletion of CD4 + lymphocytes (Karlsson et al., 1997) . These authors detected 12 amino acid changes in exterior domains of gp120 and gp41 and a deletion of 140 bp that resulted in the substitution of the carboxy terminus of BCDG SHIV highly pathogenic in cynomolgus monkey SHIV highly pathogenic in cynomolgus monkey (b) (a) Fig. 3 . Amino acid sequence alignments of SHIV Env V3 (a) and the gp41-Nef junction (b) regions of the pathogenic SHIVs. V3 amino acid sequences were deduced from genomic DNA from cynomolgus monkeys inoculated with p-SHIV and viruses of its sequential serum passages. Amino acids in the V3 loop are shown in bold. Dots indicate identity with the SHIV-89.6 sequence, the underlined region indicates the presence of a deletion and asterisks indicate stop codons.
SIVmac gp41 for that of the HIV-1 gene, suggesting that the molecular changes might be responsible for the enhanced pathogenicity of the virus. Our sequence results are similar to those of Karlsson et al. (1997) , since we detected an identical deletion of 42 amino acids in the intracytoplasmic gp41-Nef junction region, amino acid substitutions in the env C2-V3 region and in the nef gene, and also a substitution at position 746 in the Env gp41 region, after passage of p-SHIV in cynomolgus monkeys. These amino acid deletions and substitutions are identical to those found in SHIV-89.6P compared with the original SHIV-89.6 in rhesus macaques (Karlsson et al., 1997) . However, in our limited study, we also revealed three specific amino acid changes in SHIV-C2\1 at the junction between HIV-1 gp41 and SIVmac gp41 in the cytoplasmic region of the gp41 peptide ; changes from aspartate-756 to alanine, from isoleucine-779 to threonine and from leucine-842 to valine. Two of the amino acid changes were associated with a change of charge ; two of the three amino acids substituted in the C2-V3 region (Asn #(* Asp, Ala #)% Val and Arg $!) Glu) were negatively charged. These results led us to hypothesize that the deletion of amino acids in the gp41-Nef junction region, with or without additional amino acid changes in C2-V3 and the junction region, is responsible for the enhanced pathogenicity of the SHIV-C2\1 virus in cynomolgus monkeys. However, we cannot rule out that highly pathogenic virus clones incorporating these genetic changes were already present in the original SHIV isolate and were selected by in vivo passage of the virus. Studies to define BCDH K. Shinohara and others K. Shinohara and others more clearly the contribution of the molecular changes found in SHIV-C2\1 to its enhanced pathogenicity will involve generating and using the pathogenic molecular clone of this virus for sequence-swap experiments. By using in vivo passage of SHIV-C strains in naive cynomolgus monkeys, we established a pathogenic SHIV model of AIDS in a cynomolgus monkey. With regard to the acquisition of high virulence by SHIV-C2\1, the first animal inoculated with p-SHIV had a transient decrease of CD4 + T lymphocytes early after infection. However, it soon recovered and maintained CD4 + T cells for more than 6 months after the challenge. Although these results are based on a single p-SHIV-inoculated animal, we speculate that the original virus is not particularly pathogenic, since the genetic sequence of the env gene was identical to that of the non-pathogenic clone SHIV-89.6 (Karlsson et al., 1997) . However, SHIV-C2\1 certainly induced a loss of CD4 + T lymphocytes in PBMC from all cynomolgus monkeys tested. Moreover, in SHIV-C2\1-inoculated animals, CD4 + T lymphocyte depletion was detected not only in PBMC but also in various lymphoid organs at autopsy, suggesting that a profoundly immunodeficient state was induced in the animals by in vivo passage of serum from infected animals. Although the PBj14 isolates of SIVsmm were reported to be rapidly fatal in macaques (Reimann et al., 1996 b) , SHIV-C2\1-infected cynomolgus monkeys were alive even after complete depletion of circulating and tissue CD4 + lymphocytes. An explanation for the difference in the pathogenicity induced by these viruses is not readily apparent.
There is a possibility that another agent may have been copassaged and may be responsible for the clinical signs. Several factors argue against this explanation. Firstly, all cynomolgus monkeys used in this study were fed by standard operating procedures for evaluation of human vaccines in our primate centre and were used for the experiments in BL3-level facilities. We did not use any wild animals. Secondly, the serum used as the SHIV-C2\1 virus source was analysed for other pathogens and found to be free of known simian retroviruses, herpesviruses and bacteria that cause CD4 + cell loss. Thirdly, a similar evolution of SHIV to pathogenicity was observed after in vivo passage of SHIV in macaques Joag et al., 1996 ; Reimann et al., 1996 b) . Finally, CD4 + cell loss was followed by viraemia in these SHIV-C2\1-infected cynomolgus monkeys. A similar phenomenon has been reported in HIV\AIDS in humans. Thus, it is likely that the causative agent of the clinical signs in SHIV-C2\1-injected animals was SHIV-C2\1 itself.
With regard to the lack of anti-Gag antibody response in animals infected with the pathogenic SHIV-C2\1 but not with the original p-SHIV, the loss of reactivity of the SIVgag antibody in various sera from SHIV-infected monkeys appears to be associated with progress of the virus infection to an immunodeficient state, because the anti-Gag antibody response had disappeared at the time of CD4 + lymphocyte depletion in SHIV-C2\1-inoculated cynomolgus monkeys. However, antiEnv antibody production was not affected in cynomolgus monkeys infected with the pathogenic SHIV-C. The kinetics of these two kinds of antibody production might reflect different mechanisms of immune response in pathogenic SHIV infections. Similar changes in the kinetics of anti-Env and anti-Gag antibody production were also observed in HIV-1 infection of humans (Esteban et al., 1985) , supporting the finding in animal models that functional CD4 + cells are necessary to maintain effective anti-Gag immunity. Loss of Gag antibody production might reflect the loss of T-cell help, which is more necessary for the anti-Gag than the anti-Env response (Binley et al., 1997) . Thus, infection of cynomolgus monkeys with SHIV-C2\1 appears to be capable of inducing AIDS-like immune deficiency of T-cell help in these animals.
